Just like the novel coronavirus itself, the emergence of so-called long COVID has surprised both the patients who couldn’t shake their symptoms and the clinicians who have struggled to provide effective treatments. Now, as the U.S. looks to move past the pandemic, there remain unanswered questions about how this fallout from the virus might hamper some workers and for how long. These uncertainties could have important implications for workers’ compensation. By some measures, one in four patients who get COVID-19—even those with mild or asymptomatic cases—will experience subsequent symptoms that range from muscle and nerve pain to breathing difficulties to anxiety and depression. The scope of the challenge will require providers and employers to better understand the nature of the conditions, their origins, and the best paths for treatment. Watch this on-demand webinar to learn more about long COVID and the implications for workers and employers.
More stories
2022 Enlyte Technology Executive Conference
The Enlyte Technology Executive Conference (enlyteTEC) is an invite-only event featuring the most impactful innovations and insights from the exper
Workers' Compensation Institute (WCI) 2022 Conference
As the nation’s largest workers’ comp conference, WCI 2022 brings together professionals from acro
National Workers' Compensation Disability Conference & Expo (NWC&D)
The National Workers’ Compensation and Disability Conference & Expo (NWC&D) is the only n
How Miami-Dade’s Rosa Royo Forged Connection and Engagement with Infected Police Officers as the Pandemic Raged
When police officers in her school district contracted COVID, Rosa Royo and her team stepped up and guaranteed them nurse case management assistance.
Ethics in Claims and Medical Case Management
CE credit is not available for previously recorded sessions.
Examining Opioid Utilization Drug Trends
Opioid utilization in workers’ comp has steadily been trending downwards. Yet, data from Mitchell's Pharmacy Trends Report reveals other impactful discoveries for opioid therapeutic classes and dependency issues. In today’s Inside Workers’ Comp, Nikki Wilson, Pharm.D./MBA, Director, Clinical Product | Pharmacy Solutions, joins us to take a deeper dive into the data.